Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.16
BAYRY's Cash to Debt is ranked lower than
89% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. BAYRY: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08  Med: 0.31 Max: No Debt
Current: 0.16
Equity to Asset 0.30
BAYRY's Equity to Asset is ranked lower than
87% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BAYRY: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s 10-Year Equity to Asset Range
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.3
0.21
0.46
F-Score: 6
Z-Score: 2.03
M-Score: -2.55
WACC vs ROIC
8.22%
9.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.03
BAYRY's Operating margin (%) is ranked higher than
56% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. BAYRY: 10.03 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21  Med: 9.74 Max: 12.29
Current: 10.03
-4.21
12.29
Net-margin (%) 7.71
BAYRY's Net-margin (%) is ranked higher than
57% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. BAYRY: 7.71 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41  Med: 5.75 Max: 14.55
Current: 7.71
-4.41
14.55
ROE (%) 16.89
BAYRY's ROE (%) is ranked higher than
76% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. BAYRY: 16.89 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s 10-Year ROE (%) Range
Min: -9.14  Med: 11.83 Max: 31.94
Current: 16.89
-9.14
31.94
ROA (%) 5.18
BAYRY's ROA (%) is ranked higher than
57% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. BAYRY: 5.18 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s 10-Year ROA (%) Range
Min: -3.18  Med: 3.98 Max: 8.78
Current: 5.18
-3.18
8.78
ROC (Joel Greenblatt) (%) 25.92
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. BAYRY: 25.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.12  Med: 19.68 Max: 34.99
Current: 25.92
-6.12
34.99
Revenue Growth (3Y)(%) 5.00
BAYRY's Revenue Growth (3Y)(%) is ranked lower than
53% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BAYRY: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4  Med: 1.15 Max: 8.4
Current: 5
-4
8.4
EPS Growth (3Y)(%) 11.50
BAYRY's EPS Growth (3Y)(%) is ranked higher than
60% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BAYRY: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.1  Med: 5.90 Max: 51.9
Current: 11.5
-19.1
51.9
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BAYRY Guru Trades in Q3 2014

Ken Fisher 2,511,364 sh (+9.08%)
» More
Q4 2014

BAYRY Guru Trades in Q4 2014

Ken Fisher 2,493,419 sh (-0.71%)
» More
Q1 2015

BAYRY Guru Trades in Q1 2015

Ken Fisher 2,509,075 sh (+0.63%)
» More
Q2 2015

BAYRY Guru Trades in Q2 2015

Ken Fisher 4,610,296 sh (+83.74%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.50
BAYRY's P/E(ttm) is ranked higher than
56% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.60 vs. BAYRY: 27.50 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67  Med: 22.76 Max: 36.88
Current: 27.5
8.67
36.88
Forward P/E 16.00
BAYRY's Forward P/E is ranked higher than
68% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.47 vs. BAYRY: 16.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.80
BAYRY's PE(NRI) is ranked higher than
56% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. BAYRY: 28.80 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s 10-Year PE(NRI) Range
Min: 14.08  Med: 23.80 Max: 37.24
Current: 28.8
14.08
37.24
P/B 4.36
BAYRY's P/B is ranked lower than
65% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. BAYRY: 4.36 )
Ranked among companies with meaningful P/B only.
BAYRY' s 10-Year P/B Range
Min: 1.22  Med: 2.41 Max: 5.56
Current: 4.36
1.22
5.56
P/S 2.12
BAYRY's P/S is ranked higher than
61% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. BAYRY: 2.12 )
Ranked among companies with meaningful P/S only.
BAYRY' s 10-Year P/S Range
Min: 0.48  Med: 1.28 Max: 2.77
Current: 2.12
0.48
2.77
PFCF 22.47
BAYRY's PFCF is ranked higher than
73% of the 274 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.71 vs. BAYRY: 22.47 )
Ranked among companies with meaningful PFCF only.
BAYRY' s 10-Year PFCF Range
Min: 7.28  Med: 16.67 Max: 187
Current: 22.47
7.28
187
POCF 14.34
BAYRY's POCF is ranked higher than
75% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.63 vs. BAYRY: 14.34 )
Ranked among companies with meaningful POCF only.
BAYRY' s 10-Year POCF Range
Min: 5.05  Med: 9.01 Max: 19.35
Current: 14.34
5.05
19.35
EV-to-EBIT 22.27
BAYRY's EV-to-EBIT is ranked higher than
53% of the 491 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.81 vs. BAYRY: 22.27 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s 10-Year EV-to-EBIT Range
Min: -17.9  Med: 17.10 Max: 31.7
Current: 22.27
-17.9
31.7
PEG 7.58
BAYRY's PEG is ranked lower than
75% of the 257 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. BAYRY: 7.58 )
Ranked among companies with meaningful PEG only.
BAYRY' s 10-Year PEG Range
Min: 0.6  Med: 3.09 Max: 7.72
Current: 7.58
0.6
7.72
Shiller P/E 35.88
BAYRY's Shiller P/E is ranked lower than
52% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. BAYRY: 35.88 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s 10-Year Shiller P/E Range
Min: 13.49  Med: 28.21 Max: 50.98
Current: 35.88
13.49
50.98
Current Ratio 1.26
BAYRY's Current Ratio is ranked lower than
81% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BAYRY: 1.26 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s 10-Year Current Ratio Range
Min: 1  Med: 1.55 Max: 2.13
Current: 1.26
1
2.13
Quick Ratio 0.84
BAYRY's Quick Ratio is ranked lower than
83% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BAYRY: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s 10-Year Quick Ratio Range
Min: 0.64  Med: 1.01 Max: 1.44
Current: 0.84
0.64
1.44
Days Inventory 141.77
BAYRY's Days Inventory is ranked lower than
64% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.99 vs. BAYRY: 141.77 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s 10-Year Days Inventory Range
Min: 111.47  Med: 132.12 Max: 154.01
Current: 141.77
111.47
154.01
Days Sales Outstanding 90.32
BAYRY's Days Sales Outstanding is ranked lower than
62% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.80 vs. BAYRY: 90.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s 10-Year Days Sales Outstanding Range
Min: 54.89  Med: 69.37 Max: 78.61
Current: 90.32
54.89
78.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.88
BAYRY's Dividend Yield is ranked higher than
63% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. BAYRY: 1.88 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s 10-Year Dividend Yield Range
Min: 1.44  Med: 2.32 Max: 3.93
Current: 1.88
1.44
3.93
Dividend Payout 0.53
BAYRY's Dividend Payout is ranked lower than
71% of the 394 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. BAYRY: 0.53 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s 10-Year Dividend Payout Range
Min: 0.98  Med: 1.83 Max: 2.85
Current: 0.53
0.98
2.85
Dividend growth (3y) 11.90
BAYRY's Dividend growth (3y) is ranked higher than
60% of the 255 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. BAYRY: 11.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 1.80 Max: 34.9
Current: 11.9
0
34.9
Yield on cost (5-Year) 2.91
BAYRY's Yield on cost (5-Year) is ranked higher than
70% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.64 vs. BAYRY: 2.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 2.23  Med: 3.59 Max: 6.07
Current: 2.91
2.23
6.07

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.68
BAYRY's Price/Projected FCF is ranked higher than
67% of the 319 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.70 vs. BAYRY: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s 10-Year Price/Projected FCF Range
Min: 0.71  Med: 1.53 Max: 2.2
Current: 1.68
0.71
2.2
Price/Median PS Value 1.65
BAYRY's Price/Median PS Value is ranked lower than
71% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. BAYRY: 1.65 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 0.94 Max: 3.58
Current: 1.65
0.25
3.58
Earnings Yield (Greenblatt) (%) 4.44
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. BAYRY: 4.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.2  Med: 5.80 Max: 13.9
Current: 4.44
3.2
13.9
Forward Rate of Return (Yacktman) (%) 7.93
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. BAYRY: 7.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.2  Med: 13.80 Max: 31.7
Current: 7.93
2.2
31.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 50,496 52,686 54,418
EPS($) 7.24 8.10 8.66
EPS without NRI($) 7.24 8.10 8.66

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAY.Italy, BAY.Spain, BAYN N.Mexico, BAYN.Switzerland, BAYA.Germany, BAYN.Germany,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
savings Apr 22 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 

More From Other Websites
Bayer Separates Material Science Business Covestro Sep 01 2015
Bayer AG Earnings Q2, 2015 Sep 01 2015
Chipotle sued over GMO-free menu claims Aug 31 2015
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares Aug 31 2015
Bayer heart failure drug cuts deaths in mid-stage trial Aug 31 2015
Bayer to Forge Ahead With Finerenone Trials on Positive Data Aug 31 2015
Italian farm family video wins the first global web video competition -- YouFarm International... Aug 26 2015
Bayer Agrees to Increase Payout for Ex-Schering Shareholders Aug 25 2015
Hunting for new ideas: 100 young leaders develop innovative actions to tackle global food challenges Aug 24 2015
Bayer MaterialScience: 50 years of HDI production in Leverkusen Aug 21 2015
European Commission approved Terpenoid Blend QRD 460 Aug 17 2015
Research and Markets: Investigation Report on China's Sorafenib Market, 2010-2019 Aug 17 2015
Covestro Management Board named Aug 13 2015
Research and Markets: Investigation Report on China's Recombinant Factor VIII Market, 2010-2019 Aug 06 2015
The Pesticide That Kills Bugs and Might Help Fight Cancer Aug 03 2015
Will Regeneron (REGN) Earnings Surprise on Eylea Sales? - Analyst Blog Jul 31 2015
Bayer (BAYRY) Q2 Revenues Up Y/Y, 2015 Guidance Revised - Analyst Blog Jul 30 2015
Bayer reports boost in sales, income for 2Q Jul 29 2015
Bayer Earnings Beat Estimates on Xarelto and Plastics Division Jul 29 2015
Bayer CEO: No plans to acquire rival Syngenta Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK